While contrast-enhanced mammography (CEM) offered the highest agreement with histopathology on the extent of malignancy in a new study, researchers found the use of pre-op CEM had no impact on mastectomy or reoperation rates.
In a new podcast episode, Manisha Bahl, MD, MPH, FSBI, discusses recently published guidelines on proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).